The kidney, a cardiovascular risk marker, and a new target for therapy.

Both reduced filtration power and increased excretion of albumin in the urine are powerful markers for renal and cardiovascular progressive function loss. These risk markers indicate the risk above and beyond the conventional existing risk markers/factors. The risk is substantial, because both reduced filtration and microalbuminuria are highly prevalent in the general population, matching in prevalence with the most well-known risk factor, hypertension. Therapeutic interventions to preserve renal and cardiovascular function, such as with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists, are highly effective, particularly in those patients that have reduced filtration power. In addition, short-term reduction of albuminuria that follows the renin-angiotensin-aldosterone-system intervention appears to be predictive of long-term cardiovascular and renal protection. In conclusion, estimated glomerular filtration rate as well as albumin excretion in the urine are powerful predictors for cardiovascular and renal outcome and should be used as such. Intervention and prevention could be aimed at not only at reducing conventional risk markers, but also at reducing albuminuria.

[1]  E. Lewis,et al.  Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[3]  B. Dimitrov,et al.  Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. , 2004, Journal of the American Society of Nephrology : JASN.

[4]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[5]  D. de Zeeuw,et al.  An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. , 2004, Kidney international. Supplement.

[6]  B. Brenner,et al.  Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.

[7]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[8]  B. Dimitrov,et al.  Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results , 2004 .

[9]  M. Nieminen,et al.  Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study , 2003, Annals of Internal Medicine.

[10]  S. Romundstad,et al.  Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  K. Iseki,et al.  Proteinuria and the risk of developing end-stage renal disease. , 2003, Kidney international.

[12]  D. Grobbee,et al.  Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.

[13]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  Hans L Hillege,et al.  Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.

[15]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[16]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .

[17]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[18]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[19]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[20]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[21]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[22]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[23]  M. Schroll,et al.  Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. , 2000, Hypertension.

[24]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[25]  M. Schroll,et al.  Urinary albumin excretion. An independent predictor of ischemic heart disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[26]  W. Kannel,et al.  The prognostic significance of proteinuria: the Framingham study. , 1984, American heart journal.

[27]  C. Mogensen,et al.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. , 1984, The New England journal of medicine.